Chaitali Kalpataru Shah

Bacil Pharma Board approved unaudited standalone and consolidated financial results for Q2 and H1 ended September 30, 2026. Standalone Q2 profit after tax was ₹0 lakh with total revenue of ₹9.18 lakh,